Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 19/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.61 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5621615 | 0.99 | PTGER1 (0.74) | PTGER1CYP2C9CYP3A4CYP2C19TBXA2R | |
| SCHEMBL14067165 | 0.97 | PTGER1 (0.73) | PTGER1CYP2C9CYP3A4CYP2C19TBXA2R | |
| SCHEMBL4914607 | 0.96 | PTGER1 (0.71) | PTGER1CYP2C9CYP3A4CYP2C19TBXA2R | |
| SCHEMBL4914512 | 0.96 | PTGER1 (0.71) | PTGER1CYP2C9CYP3A4CYP2C19TBXA2R | |
| SCHEMBL5619851 | 0.95 | PTGER1 (0.75) | PTGER1CYP2C9CYP3A4CYP2C19TBXA2R | |
| SCHEMBL4923155 | 0.94 | PTGER1 (0.79) | PTGER1CYP2C9CYP3A4CYP2C19TBXA2R | |
| SCHEMBL5621186 | 0.93 | PTGER1 (0.80) | PTGER1CYP2C9CYP3A4CYP2C19TBXA2R | |
| SCHEMBL5619999 | 0.93 | PTGER1 (0.69) | PTGER1CYP2C9CYP3A4CYP2C19TBXA2R | |
| SCHEMBL5620343 | 0.93 | PTGER1 (0.69) | PTGER1CYP2C9CYP3A4CYP2C19TBXA2R | |
| SCHEMBL5621317 | 0.93 | PTGER1 (0.68) | PTGER1CYP2C9CYP3A4CYP2C19TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234335-A1 | Cyclohexene Compounds | GLAXO GROUP LIMITED (GB) | 2008-09-25 | — | — | US | claimed |
| EP-1670764-A1 | CYCLOHEXENE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-06-21 | — | — | EP | claimed |
| WO-2005037794-A1 | CYCLOHEXENE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | claimed |
| US-20080234335-A1 | Cyclohexene Compounds | GLAXO GROUP LIMITED (GB) | 2008-09-25 | — | — | US | disclosed |
| EP-1670764-A1 | CYCLOHEXENE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005037794-A1 | CYCLOHEXENE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234335-A1 | Cyclohexene Compounds | C1R, CYP1B1, CYP2C9 | PTGER1 377/4885CYP2C9 3/4885CYP3A4 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.